Amprenavir
General information:
| Withdrawn ID: | 837 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | J05AE05 |
| Molecular Formula: | C25H35N3O6S |
| Molweight: | 505.627 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | No |
|---|---|
| First approved: | 1999 |
| First withdrawn: | 2004 |
| Last withdrawn: | 2004 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Amprenavir as primary suspect: | 7 |
|---|
Reported final outcomes:
| Hospitalization (initial or prolonged): | 1 |
|---|
Reported side-effects:
| Side-effect | Case number |
|---|---|
| LIPASE INCREASED | 1 |
| ACANTHOSIS NIGRICANS | 1 |
| ASTHENIA | 1 |
| BLOOD CHOLESTEROL INCREASED | 1 |
| CD4 LYMPHOCYTES DECREASED | 1 |
| DEPRESSION | 1 |
| HEPATOCELLULAR DAMAGE | 1 |
| HYPERGLYCAEMIA | 1 |
| INSOMNIA | 1 |
| INSULIN RESISTANCE | 1 |
| VIRAL LOAD INCREASED | 1 |
| LIPODYSTROPHY ACQUIRED | 1 |
| MUCOSAL ULCERATION | 1 |
| PARAESTHESIA CIRCUMORAL | 1 |
| PHARYNX DISCOMFORT | 1 |
| PRURITUS | 1 |
| RASH | 1 |
| RASH MACULO-PAPULAR | 1 |
| TOXIC SKIN ERUPTION | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P02545 | 631 | Prelamin-A/C | LMNA_HUMAN |
| P24557 | 6727 | Thromboxane-A synthase | THAS_HUMAN |
Toxicity information:
| Toxicity type: | N/A |
|---|
External links:
| ChEBML: | CHEMBL116 |
|---|---|
| DrugBank: | DB00701 |